About
Inotiv is a full-service contract research organization (CRO) offering comprehensive nonclinical drug discovery and development solutions. The company serves pharmaceutical, biotechnology, and medical device clients across therapeutic areas including oncology, neuroscience, cardiovascular, metabolic disease, inflammation, and infectious disease. Inotiv's service portfolio spans the entire preclinical pipeline: Discovery and Translational Sciences (including in vitro and in vivo disease pharmacology, DMPK, bioanalysis, and biomarkers), Safety Assessment (general toxicology, genetic toxicology, safety pharmacology, developmental and reproductive toxicology, and carcinogenicity), and Cell and Gene Therapy support. The company also provides pathology, histology, digital pathology with AI-driven image analysis, and targeted proteomics. In addition to laboratory services, Inotiv supplies research models and related services, including genetically engineered models (GEMS), contract breeding, biospecimen services, custom antibody production, and health monitoring. Supporting resources include proprietary LIMS software (Eusoft Labs™ and LabTracks™) and Teklad™ laboratory animal diets, bedding, and enrichment products. Inotiv's specialized capabilities in mass spectrometry assays for Antibody Drug Conjugates (ADCs), predictive and computational toxicology, and toxicogenomics make it a strong partner for advanced therapeutic development. It is suited for scientists, researchers, and drug development teams at pharmaceutical companies and academic institutions seeking a reliable CRO with global reach.
Key Features
- Comprehensive Safety Assessment: Offers GLP and non-GLP toxicology studies including general, genetic, developmental, reproductive, and safety pharmacology to meet international regulatory requirements.
- Research Models & Services: Provides a broad portfolio of research models by therapeutic area, genetically engineered models (GEMS), contract breeding, biospecimen services, and full-spectrum health monitoring.
- Discovery & Translational Sciences: Supports early-stage drug discovery with in vitro and in vivo disease pharmacology, DMPK, predictive/computational toxicology, targeted proteomics, and cell and molecular biology.
- Digital Pathology & AI Image Analysis: Delivers whole slide imaging and precision AI-driven quantitative image analysis to support drug discovery and development histopathology projects.
- ADC Mass Spectrometry Assays: Specialized assays to quantify Antibody Drug Conjugate target proteins in any sample type, including FFPE tissue, supporting oncology and other therapeutic ADC programs.
Use Cases
- Pharmaceutical companies conducting IND-enabling toxicology studies to support regulatory submissions.
- Biotech firms requiring in vitro and in vivo disease pharmacology to validate drug candidates in specific therapeutic areas.
- Drug developers needing GLP bioanalytical support for large or small molecule quantification during clinical trial preparation.
- Research teams seeking genetically engineered or specialty in vivo models for translational oncology or neuroscience studies.
- ADC therapeutic developers requiring mass spectrometry assays to quantify ADC target proteins without antibody-based methods.
Pros
- Full-Spectrum CRO Capabilities: Covers the entire preclinical pipeline from discovery through IND-enabling and pre-marketing authorization, reducing the need to work with multiple vendors.
- Specialized Research Models: Offers an extensive catalog of research models, including genetically engineered and therapeutic-area-specific models, backed by in-house health monitoring and genetic testing.
- Proprietary Software & Resources: Provides proprietary LIMS tools (Eusoft Labs™, LabTracks™) and specialized Teklad™ diets and enrichment products to support reproducible, high-quality research.
Cons
- Enterprise-Focused Pricing: Services are tailored to pharmaceutical and biotech companies; pricing and access may not be practical for small academic labs or individual researchers.
- No Self-Service Platform: Unlike SaaS tools, all services require direct engagement and project scoping with Inotiv teams, which may slow down initial project startup.
- Niche Audience: Highly specialized for drug development and life sciences; not applicable outside of pharmaceutical, biotech, or medical device research contexts.
Frequently Asked Questions
What types of studies does Inotiv offer?
Inotiv offers a wide range of nonclinical studies including general toxicology, genetic toxicology, safety pharmacology, developmental and reproductive toxicology, carcinogenicity, bioanalysis (large and small molecule), DMPK, and histopathology, among others.
What therapeutic areas does Inotiv cover?
Inotiv provides services across cardiovascular, gastrointestinal, hepatic, infectious disease, inflammation and immunology, metabolic and diabetic disease, neuroscience, pulmonary, oncology, and renal therapeutic areas.
Does Inotiv provide GLP-compliant studies?
Yes, Inotiv conducts both GLP and non-GLP studies, including GLP bioanalysis for large and small molecules, and GLP genetic toxicology studies, to meet regulatory submission requirements.
What research models does Inotiv supply?
Inotiv offers a broad portfolio of in vivo research models organized by therapeutic area, including genetically engineered models (GEMS), with supporting services like contract breeding, biospecimen collection, genetic testing, and health monitoring.
How can I get pricing or start a project with Inotiv?
Prospective clients can contact Inotiv directly through their website to discuss study design, project management, and pricing. Research model pricing is also available via their annual Product Guide.
